National GMA Post-market Clinical Follow-up Study (GRACE)
NCT ID: NCT05636709
Last Updated: 2025-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
350 participants
OBSERVATIONAL
2022-01-11
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Inflammatory activity in IBD is associated with an increase in peripheral blood activated granulocytes and monocyte-macrophages and intestinal infiltration by these inflammatory cells, which are largely responsible for tissue damage. In recent years, observational, prospective studies and meta-analyses of these studies have contributed to consider granulocytapheresis (GMA) as an effective and safe alternative in the treatment of UC.
This apheresis technique is based on recirculation of the patient's blood through a circuit with cellulose acetate spheres that perform a selective elimination of granulocytes and monocyte-macrophages leading to a reduction in pro-inflammatory cytokines and adhesion molecule expression, and an increase in anti-inflammatory mediators. These events in the GMA column are followed by other immunological changes, most notably a decrease in CD10+ (activated) neutrophils, leading to a compensation from the bone marrow of a CD10- (immature) neutrophil population.
GMA can be considered as a therapeutic alternative in corticodependent IBD, especially in UC. In addition, it can reduce or limit the need for corticosteroids, so another possible application is as a "bridge" treatment in patients starting treatment with thiopurine immunomodulators. A beneficial effect can also be obtained by combining apheresis with biological treatments, especially after a partial response or loss of response to these treatments. Finally, some extraintestinal manifestations associated with IBD may also benefit from its use.
The GRACE study is proposed for the evaluation of the efficacy of GMA with Adacolumn® under real conditions of use and according to the indications described in the instructions for use of the medical device.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative Colitis
NCT00702611
Adacolumn in Refractory UC Patients Trial
NCT01481142
Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases
NCT06944873
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)
NCT03566823
Postoperative REcurrence and DynamICs of T Cell Subsets in Crohn's Disease
NCT02770495
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A national, multicentre, noninterventional post-market clinical follow-up (PMCF) study with an estimated follow-up period of 12 months after completion of GMA therapy to evaluate the efficacy of Adacolumn® GMA in actual conditions of use, as specified in the product instructions for use, in adult patients diagnosed with UC or CD. Approximately 350 patients from about 30 centres in Spain are planned to be included.
The standard regimen according to product instructions for use is one session per week for 5 consecutive weeks, although in specific cases continuous regimens have been established for maintenance (one or two sessions per month) or others for induction (two sessions per week). The use of a higher number of sessions seems to increase efficacy from 40% with 5 sessions to 80% with 10 in the more refractory cases and may achieve a greater reduction in steroid use. In Europe, where GMA is used in different scenarios, it is routinely being used in 7 to 10 sessions.
The study will consist of a maximum of 4 visits: a baseline visit, which will coincide with patient inclusion in the study, and 3 follow-up visits at 4 (±2 weeks) (month 1), 24 (±2 weeks) (month 6) and 48 (±2 weeks) (month 12) weeks after the last session of induction apheresis.
All visits scheduled during the study will coincide with any of the patient visits made as part of routine clinical follow-up, without interfering with the investigator's clinical duties. Note: In the event that a patient discontinues Adacolumn® GMA, the reasons for discontinuation of the procedure will be recorded and the change in treatment for IBD, if any.
Once the patient has been adequately informed, his/her eligibility has been confirmed and he/she has signed the informed consent (IC), the investigator will start data collection in an appropriate and precise manner. Therefore, no diagnostic or therapeutic intervention outside of routine clinical practice will be applied. To ensure the noninterventional nature of the study, the data will be collected provided they are available in the patient's medical record or can be collected during patient visits to his/her physician as part of actual clinical care (as in the case of questionnaires used as source documents).
Adacolumn® is a medical device intended for modifying the biological or chemical composition of the blood (class IIb), according to Regulation (UE) 2017/745 on Medical Devices, manufactured by Japan Immnunoresearch Laboratories, JIMRO (Takasaki, Japan). It consists of a 335 ml column formed by cellulose acetate beads of 2 mm in diameter bathed in saline, where granulocytes (65%), monocytes (55%), and only 2% of lymphocytes are selectively adsorbed.
Adacolumn® is indicated for induction of remission in patients with IBD (active UC and CD), for suppression of subjective and objective symptoms in patients with rheumatoid arthritis in the inflammatory stage whose symptoms might be resistant to standard drug therapy, for treatment of patients with ocular Behcet disease and for treatment of patients with systemic lupus erythematosus.
In this study, the intended use of Adacolumn® is for application of GMA in patients diagnosed with IBD, both UC and CD
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adacolumn
Non interventional study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Established diagnosis of UC or CD according to ECCO criteria.
3. Patients in whom the physician in charge of treatment decides to start treatment with GMA and independently of their inclusion in the study.
4. Patients who understand and voluntarily sign informed consent.
Exclusion Criteria
2. Patient who is participating in a clinical trial.
NOTE: If the physician knows or suspects that the patient is unable to understand the implications of his/her participation in the study, the patient should not enter without the signature of his/her legal representative
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Adacyte Therapeutics SL
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose Luis Cabriada
Role: STUDY_CHAIR
H. Galdakao
Iago Rodríguez
Role: STUDY_CHAIR
H. Galdakao
Daniel Ginard
Role: STUDY_CHAIR
H. Son Espases
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
H. Albacete
Albacete, Albacete, Spain
H. General de Alicante
Alicante, Alicante, Spain
H. Germans Trias i Pujol
Badalona, Barcelona, Spain
H. Vall d´hebron
Barcelona, Barcelona, Spain
H. Galdakao
Galdakao, Bizkaia, Spain
H. General de Castellón
Castellon, Castellón, Spain
H. Puerta del Mar
Cadiz, Cádiz, Spain
H. Reina Sofía
Córdoba, Córdoba, Spain
H. Donostia
San Sebastián, Gipuzkoa, Spain
H. Virgen de las Nieves
Granada, Granada, Spain
H. Guadalajara
Guadalajara, Guadalajara, Spain
H. San Jorge
Huesca, Huesca, Spain
H. Santiago
Santiago de Compostela, La Coruña, Spain
H. San Pedro
Logroño, La Rioja, Spain
H. Dr. Negrín
Las Palmas de Gran Canaria, Las Palmas de Gran Canarias, Spain
H. 12 de octubre
Madrid, Madrid, Spain
H. La Paz
Madrid, Madrid, Spain
H. Costa del Sol
Marbella, Málaga, Spain
H. Navarra
Pamplona, Navarre, Spain
H. Río Carrión
Palencia, Palencia, Spain
H. Son Espases
Palma de Mallorca, Palma de Mallorca, Spain
H. Son Llatzer
Palma de Mallorca, Palma de Mallorca, Spain
H. Álvaro Cunqueiro
Vigo, Pontevedra, Spain
H. Univ. de Canarias
San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
H. Ntra. Sra. de Candelaria
Santa Cruz de Tenerife, Santa Cruz de Tenerife, Spain
H. Virgen del Rocío
Seville, Sevilla, Spain
H. Clínico Univ. de Valencia
Valencia, Valencia, Spain
H. General de Valencia
Valencia, Valencia, Spain
H. La Fe
Valencia, Valencia, Spain
H. Virgen de la Concha
Zamora, Zamora, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Maria del Mar Blasco
Role: primary
Laura Sempere
Role: primary
Eugeni Domenech
Role: primary
Claudia Herrera
Role: primary
José Luis Cabriada
Role: primary
Marga Muñoz
Role: primary
Alejandro Viejo
Role: primary
Eva Iglesias
Role: primary
Ana Muñagorri
Role: primary
Antonio Damián Sánchez
Role: primary
Sonia Arribas
Role: primary
Miguel Montoro
Role: primary
Manuel Barreiro
Role: primary
María Calvo
Role: primary
Daniel Ceballos
Role: primary
María Algara
Role: primary
María Dolores Martín
Role: primary
Francisco Fernández
Role: primary
Miren Acuña
Role: primary
Francisco Rancel
Role: primary
Daniel Ginard
Role: primary
Joan Riera
Role: primary
Vicente Hernández
Role: primary
Laura Ramos
Role: primary
Alejandro Hernández
Role: primary
Eduardo Leo
Role: primary
Maia Boscá
Role: primary
José Mª Huguet
Role: primary
Guillermo Bastida
Role: primary
Paola Fradejas
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GRACE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.